Cortex Pharmaceuticals, Shire Pharmaceuticals Group plc deal

COR said SHP did not exercise an option to develop COR’s Ampakine technology and compounds including CX516 (SPD420) to treat attention deficit hyperactivity disorder (ADHD). SHP’s decision followed re...